Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions
2024
· University Medical Center Utrecht,
· Respiratory Syncytial Virus NETwork (ReSViNET) Foundation
This article focuses on respiratory syncytial virus (RSV) infections that occur outside of hospitals. It describes new ways to prevent these infections, which are common …
Ask aRCie
Rapid Review Showed That Real-World Results on How Nirsevimab Prevented Respiratory Syncytial Virus Hospitalisations Were Similar to Randomised Trials
This brief report describes a study on nirsevimab, a treatment to prevent RSV hospitalizations in infants. Real-world results from studies in Luxembourg, Spain, and the …
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows …
Nirsevimab Clinical Guidance and VFC Ordering [Letter]
This letter provides clinical guidance on the use of nirsevimab (Beyfortus), a monoclonal antibody that protects infants and toddlers from respiratory syncytial virus (RSV). Information …
Nirsevimab Updates
This webinar provides updates on nirservimab. Providers will learn about the RSV season in Hawaii, the recommended immunizations for RSV prevention, and best practices for …
Obtaining Beyfortus Through the Vaccines for Children Program
This webpage explains how birthing hospitals can acquire Beyfortus through the Vaccines for Children (VFC) program. Hospitals can get Beyfortus through direct purchase or the …
Nirsevimab for RSV Prevention in Late Preterm and Term Infants | NEJM
2022
· NEJM Group
This short video summarizes new research findings on nirsevimab and how it can prevent RSV in late preterm and term infants. The trial included 1490 …
Preventing RSV in Babies: A Scientific Milestone
This 3-minute video discusses the use of nirsevimab (Beyfortus™) to protect vulnerable infants from RSV. Dr. Paul Offit explains its benefits, clinical trial results, and …
Beyfortus (nirsevimab) Now Available Through VFC
This announcement explains that providers can order nirsevimab (Beyfortus) through Vaccines for Children (VFC). It covers the following areas of consideration: dosage and administration, eligible …
Impact of Nirsevimab on Admission to a Spanish Pediatric Intensive Care Unit Because of RSV Bronchiolitis: Unicentric Observational Study from 2017 to 2024
This letter describes admissions to a pediatric critical care unit (PICU) because of acute bronchiolitis caused by respiratory syncytial virus. The study looked at a …